Korean Drug Co., Ltd. (KOSDAQ: 014570)
South Korea
· Delayed Price · Currency is KRW 4,995.00
-45.00 (-0.89%)
Oct 11, 2024, 9:00 AM KST
Korean Drug Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 77,923 | 81,375 | 79,984 | 74,466 | 66,789 | 55,529 | Upgrade
|
| Other Revenue | -0 | -0 | -0 | -0 | - | 0 | Upgrade
|
| Revenue | 77,923 | 81,375 | 79,984 | 74,466 | 66,789 | 55,529 | Upgrade
|
| Revenue Growth (YoY) | -6.12% | 1.74% | 7.41% | 11.49% | 20.28% | 6.73% | Upgrade
|
| Cost of Revenue | 40,579 | 44,025 | 45,467 | 43,400 | 38,100 | 34,221 | Upgrade
|
| Gross Profit | 37,343 | 37,350 | 34,517 | 31,065 | 28,689 | 21,308 | Upgrade
|
| Selling, General & Admin | 18,234 | 18,136 | 19,111 | 18,529 | 16,530 | 16,944 | Upgrade
|
| Other Operating Expenses | 747.47 | 724.2 | 662 | 745.93 | 662.9 | 604.23 | Upgrade
|
| Operating Expenses | 35,671 | 30,630 | 20,188 | 19,799 | 17,650 | 17,892 | Upgrade
|
| Operating Income | 1,672 | 6,720 | 14,329 | 11,266 | 11,039 | 3,416 | Upgrade
|
| Interest Expense | -4.07 | -3.02 | -2.1 | -1.53 | -3.13 | -3.97 | Upgrade
|
| Interest & Investment Income | 865.46 | 1,213 | 621.01 | 133.66 | 166.91 | 63.21 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | -576.86 | -23.11 | Upgrade
|
| Currency Exchange Gain (Loss) | -15.08 | 1.55 | 84.73 | 98.22 | -74.65 | 20.95 | Upgrade
|
| Other Non Operating Income (Expenses) | 197.01 | 205.88 | 32.88 | 182.37 | 227.81 | 180.23 | Upgrade
|
| EBT Excluding Unusual Items | 2,715 | 8,137 | 15,066 | 11,679 | 10,779 | 3,654 | Upgrade
|
| Gain (Loss) on Sale of Investments | -96.6 | 132.87 | -383.6 | -359.46 | -1,534 | 737.9 | Upgrade
|
| Gain (Loss) on Sale of Assets | 0.02 | -4.78 | 2.81 | 1.13 | -5.28 | 58.65 | Upgrade
|
| Pretax Income | 2,619 | 8,265 | 14,685 | 11,321 | 9,240 | 4,450 | Upgrade
|
| Income Tax Expense | 3,861 | 13,182 | 2,876 | 2,278 | 1,880 | 554.93 | Upgrade
|
| Net Income | -1,242 | -4,917 | 11,809 | 9,042 | 7,360 | 3,895 | Upgrade
|
| Net Income to Common | -1,242 | -4,917 | 11,809 | 9,042 | 7,360 | 3,895 | Upgrade
|
| Net Income Growth | - | - | 30.60% | 22.86% | 88.94% | -40.64% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 | Upgrade
|
| Shares Change (YoY) | -0.21% | -0.01% | -1.25% | 0.46% | -0.37% | -0.07% | Upgrade
|
| EPS (Basic) | -115.33 | -455.98 | 1095.00 | 828.00 | 677.00 | 357.00 | Upgrade
|
| EPS (Diluted) | -115.33 | -455.98 | 1095.00 | 828.00 | 677.00 | 357.00 | Upgrade
|
| EPS Growth | - | - | 32.25% | 22.30% | 89.64% | -40.60% | Upgrade
|
| Free Cash Flow | -13,829 | -7,812 | -180.15 | 7,660 | 11,592 | 3,156 | Upgrade
|
| Free Cash Flow Per Share | -1284.03 | -724.50 | -16.70 | 701.43 | 1066.29 | 289.26 | Upgrade
|
| Gross Margin | 47.92% | 45.90% | 43.16% | 41.72% | 42.96% | 38.37% | Upgrade
|
| Operating Margin | 2.15% | 8.26% | 17.91% | 15.13% | 16.53% | 6.15% | Upgrade
|
| Profit Margin | -1.59% | -6.04% | 14.76% | 12.14% | 11.02% | 7.01% | Upgrade
|
| Free Cash Flow Margin | -17.75% | -9.60% | -0.23% | 10.29% | 17.36% | 5.68% | Upgrade
|
| EBITDA | 3,677 | 8,469 | 15,712 | 12,736 | 12,394 | 4,601 | Upgrade
|
| EBITDA Margin | 4.72% | 10.41% | 19.64% | 17.10% | 18.56% | 8.29% | Upgrade
|
| D&A For EBITDA | 2,005 | 1,749 | 1,383 | 1,470 | 1,355 | 1,184 | Upgrade
|
| EBIT | 1,672 | 6,720 | 14,329 | 11,266 | 11,039 | 3,416 | Upgrade
|
| EBIT Margin | 2.15% | 8.26% | 17.91% | 15.13% | 16.53% | 6.15% | Upgrade
|
| Effective Tax Rate | 147.43% | 159.49% | 19.58% | 20.12% | 20.35% | 12.47% | Upgrade
|
| Advertising Expenses | - | 920.23 | 1,014 | 1,082 | 1,231 | 1,437 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.